NCT00668642 2023-08-22
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Endeavor Health
Phase 2 Completed
Clinical Trials
10 trialsNCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT05705700 2023-02-27
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00985738 2016-05-17
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT01368003 2015-09-01
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT00403000 2013-05-01
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Roswell Park Cancer Institute
Phase 2 Completed